Hospital
Eoh Acquisition Group, LLC
Eoh Acquisition Group, LLC was paid $41.15M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoEOH ACQUISITION GROUP, LLC
EAST ORANGE, NJ 07018
EAST ORANGE, NJ 07018
33aNPI1013386143assigned 09/18/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.15M
24GClaims903,130
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#38 of 93
Median peer was paid$30.60M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 146,916 | $7.62M | |
| 2019 | 143,814 | $6.58M | |
| 2020 | 94,465 | $3.74M | |
| 2021 | 136,632 | $5.85M | |
| 2022 | 178,878 | $7.86M | |
| 2023 | 124,411 | $5.53M | |
| 2024incomplete | 78,014 | $3.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 39,133 | 35,662 | $8.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 29,820 | 27,002 | $7.22M |
| G0378 | Hospital observation service, per hour | 8.3% | 2,878 | 2,061 | $3.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 11,358 | 10,342 | $3.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.1% | 15,247 | 14,054 | $2.51M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 5.1% | 34,537 | 17,714 | $2.09M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.9% | 30,240 | 26,153 | $1.19M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.1% | 4,341 | 1,267 | $860K |
| OP710 | 1.3% | 2,577 | 2,365 | $551K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 14,243 | 11,015 | $446K |
| OP370 | <1% | 4,590 | 4,173 | $371K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 9,547 | 3,931 | $370K |
312 more codes
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 810 | $351K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 1,833 | $314K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,686 | $313K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 637 | $302K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,915 | $302K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,788 | $275K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16,185 | $251K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,833 | $238K |
| 90999 | Dialysis (unlisted procedure) | <1% | 3,395 | $227K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,309 | $227K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,344 | $216K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,931 | $209K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,049 | $208K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,676 | $205K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,056 | $201K |
| 80053 | Comprehensive metabolic panel | <1% | 31,414 | $197K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,784 | $187K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,721 | $181K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,101 | $178K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 319 | $172K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,430 | $171K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,641 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,313 | $145K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,848 | $142K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,189 | $135K |
| OP272 | <1% | 2,291 | $134K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,248 | $125K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,630 | $121K |
| OP259 | <1% | 15,808 | $111K | |
| 80320 | <1% | 5,336 | $110K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,324 | $107K |
| 97010 | <1% | 11,811 | $102K | |
| 97597 | <1% | 1,240 | $101K | |
| J3490 | Unclassified drugs | <1% | 30,540 | $94K |
| 29581 | <1% | 379 | $94K | |
| OP270 | <1% | 3,779 | $93K | |
| OP250 | <1% | 14,696 | $91K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,357 | $89K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,696 | $87K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,247 | $83K |
| 90937 | <1% | 265 | $81K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,152 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,359 | $74K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 1,394 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,132 | $66K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,799 | $66K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,985 | $63K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,421 | $63K |
| 73562 | <1% | 3,057 | $63K | |
| OP279 | <1% | 8,847 | $62K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 471 | $58K |
| 97161 | <1% | 1,575 | $58K | |
| 85027 | <1% | 20,440 | $57K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,430 | $57K |
| 72110 | <1% | 1,187 | $57K | |
| 76830 | Ultrasound, transvaginal | <1% | 702 | $56K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,437 | $55K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 3,349 | $55K |
| 84484 | <1% | 11,468 | $55K | |
| 81025 | <1% | 21,191 | $53K | |
| 20610 | <1% | 1,370 | $52K | |
| 97014 | <1% | 2,691 | $52K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 96 | $52K |
| OP258 | <1% | 2,192 | $51K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,959 | $47K |
| 97803 | <1% | 2,439 | $47K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,571 | $46K |
| 73030 | <1% | 2,248 | $46K | |
| 86710 | <1% | 4,537 | $44K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,528 | $42K |
| 93970 | <1% | 467 | $39K | |
| 73630 | <1% | 1,829 | $36K | |
| 81001 | <1% | 21,959 | $35K | |
| 83880 | <1% | 3,132 | $35K | |
| 93000 | <1% | 2,479 | $34K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,844 | $34K |
| 73130 | <1% | 1,776 | $32K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,533 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,035 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 186 | $30K |
| 72100 | <1% | 1,068 | $29K | |
| 85610 | <1% | 7,846 | $29K | |
| 80329 | <1% | 810 | $27K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,400 | $27K |
| 73502 | <1% | 1,109 | $26K | |
| 97802 | <1% | 544 | $25K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 29,880 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,343 | $24K |
| 86900 | <1% | 1,567 | $23K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 617 | $23K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 673 | $23K |
| 73610 | <1% | 1,284 | $23K | |
| 83690 | <1% | 8,068 | $21K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,090 | $20K |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,969 | $18K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,787 | $17K |
| 85730 | <1% | 4,308 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,195 | $17K |
| 97124 | <1% | 935 | $16K | |
| 93971 | <1% | 422 | $16K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,978 | $16K |
| 73560 | <1% | 478 | $15K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 476 | $15K |
| 82948 | <1% | 7,055 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,459 | $14K |
| A9270 | Non-covered item or service | <1% | 4,781 | $14K |
| 73620 | <1% | 492 | $14K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,023 | $14K |
| 80061 | Lipid panel | <1% | 2,098 | $13K |
| 72050 | <1% | 285 | $13K | |
| 90714 | <1% | 1,515 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,999 | $12K |
| OP379 | <1% | 327 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,166 | $12K |
| 73110 | <1% | 610 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,374 | $11K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 988 | $11K |
| 86850 | <1% | 1,404 | $11K | |
| 87634 | <1% | 533 | $11K | |
| 97116 | <1% | 1,446 | $11K | |
| 83605 | <1% | 2,053 | $10K | |
| 76642 | <1% | 75 | $10K | |
| 83735 | <1% | 4,026 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,002 | $10K |
| 97032 | <1% | 3,710 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $10K |
| 73600 | <1% | 335 | $9K | |
| 86901 | <1% | 1,509 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 228 | $9K |
| 36600 | <1% | 349 | $9K | |
| 84520 | <1% | 605 | $9K | |
| 82962 | <1% | 2,818 | $9K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 158 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,463 | $8K |
| 73120 | <1% | 300 | $8K | |
| 84100 | <1% | 1,309 | $8K | |
| 70486 | <1% | 191 | $8K | |
| 87340 | <1% | 400 | $8K | |
| 76641 | <1% | 85 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,730 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 446 | $7K |
| 58558 | <1% | 12 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,083 | $7K |
| 85379 | <1% | 2,158 | $7K | |
| 84702 | <1% | 1,543 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,030 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,511 | $7K |
| 94060 | <1% | 76 | $7K | |
| 77080 | <1% | 112 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 920 | $7K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,142 | $6K |
| 87070 | <1% | 1,685 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 79 | $6K |
| 12001 | <1% | 182 | $6K | |
| 0012A | <1% | 167 | $5K | |
| 86803 | <1% | 822 | $5K | |
| 87040 | <1% | 688 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,206 | $5K |
| 82550 | <1% | 2,309 | $5K | |
| 80076 | <1% | 1,198 | $5K | |
| A4657 | Syringe, with or without needle, each | <1% | 473 | $5K |
| J1270 | Injection, doxercalciferol, 1 mcg | <1% | 1,035 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 791 | $4K |
| 96127 | <1% | 268 | $4K | |
| 83970 | <1% | 158 | $4K | |
| 0011A | <1% | 174 | $4K | |
| 99024 | <1% | 329 | $4K | |
| 11043 | <1% | 51 | $4K | |
| 82728 | <1% | 187 | $4K | |
| 88312 | <1% | 334 | $4K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 4,497 | $4K |
| 97162 | <1% | 182 | $4K | |
| 94760 | <1% | 466 | $4K | |
| 84703 | <1% | 529 | $3K | |
| 84704 | <1% | 292 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $3K |
| 73590 | <1% | 144 | $3K | |
| 10060 | <1% | 53 | $3K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,789 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,062 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 355 | $3K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 69 | $3K |
| 81514 | <1% | 138 | $3K | |
| 83550 | <1% | 163 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 863 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,368 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 228 | $2K |
| 99000 | <1% | 1,914 | $2K | |
| 82553 | <1% | 264 | $2K | |
| 85014 | <1% | 145 | $2K | |
| 85018 | <1% | 144 | $2K | |
| A4300 | Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access | <1% | 2,231 | $2K |
| 29125 | <1% | 83 | $2K | |
| 80305 | <1% | 47 | $2K | |
| 86735 | <1% | 214 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 209 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 860 | $2K |
| 83540 | <1% | 151 | $2K | |
| 87806 | <1% | 169 | $2K | |
| 87341 | <1% | 68 | $2K | |
| OP637 | <1% | 1,858 | $2K | |
| 72070 | <1% | 53 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 60 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 861 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 90 | $2K |
| 74021 | <1% | 53 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,942 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,793 | $1K |
| 88300 | <1% | 126 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 145 | $1K |
| 86706 | <1% | 38 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,782 | $1K |
| 86705 | <1% | 56 | $1K | |
| 73521 | <1% | 43 | $1K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 12 | $1K |
| 99223 | Prolong inpt eval add15 m | <1% | 12 | $1K |
| 85651 | <1% | 418 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,072 | $1K |
| 76801 | <1% | 29 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 35 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 245 | $980.01 |
| 73080 | <1% | 37 | $966.37 | |
| 72040 | <1% | 51 | $943.74 | |
| 96376 | <1% | 83 | $913.94 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 138 | $889.17 |
| J1815 | Injection, insulin, per 5 units | <1% | 976 | $874.77 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 113 | $822.26 |
| 76536 | <1% | 12 | $788.01 | |
| 82803 | <1% | 109 | $786.81 | |
| 73090 | <1% | 43 | $783.48 | |
| 74019 | <1% | 38 | $775.77 | |
| A6214 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing | <1% | 371 | $767.86 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 165 | $765.77 |
| 86709 | <1% | 29 | $744.44 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $692.56 |
| 99252 | <1% | 13 | $666.42 | |
| 76496 | <1% | 14 | $660.20 | |
| 94664 | <1% | 16 | $624.62 | |
| 93307 | <1% | 14 | $595.43 | |
| 99386 | <1% | 49 | $594.51 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $593.99 |
| 99385 | <1% | 27 | $593.51 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 327 | $587.74 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,097 | $575.86 |
| 71101 | <1% | 14 | $573.82 | |
| 76775 | <1% | 13 | $569.90 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 171 | $568.77 |
| V2632 | Posterior chamber intraocular lens | <1% | 30 | $555.39 |
| 99201 | <1% | 30 | $540.95 | |
| 0013A | <1% | 26 | $522.00 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 13 | $493.97 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,105 | $479.31 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 363 | $476.55 |
| 99205 | Prolong outpt/office vis | <1% | 13 | $473.64 |
| 84132 | <1% | 497 | $459.33 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 12 | $444.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 145 | $442.74 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 133 | $392.73 |
| 73552 | <1% | 12 | $390.79 | |
| 88304 | <1% | 32 | $388.30 | |
| OP276 | <1% | 25 | $382.35 | |
| 90839 | <1% | 17 | $382.02 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 66 | $366.64 |
| 97165 | <1% | 12 | $347.54 | |
| 82330 | <1% | 72 | $325.33 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 40 | $318.27 |
| 87081 | <1% | 98 | $314.57 | |
| 84439 | <1% | 231 | $312.57 | |
| 74018 | <1% | 12 | $290.14 | |
| 12011 | <1% | 14 | $270.79 | |
| 72131 | <1% | 14 | $270.11 | |
| 29130 | <1% | 28 | $265.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 412 | $261.83 |
| 80185 | <1% | 35 | $242.25 | |
| 87110 | <1% | 12 | $240.17 | |
| 82150 | <1% | 75 | $227.18 | |
| 82607 | <1% | 134 | $226.07 | |
| 86920 | <1% | 19 | $200.76 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 354 | $199.54 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 375 | $190.99 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 25 | $183.25 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 25 | $174.86 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 32 | $156.24 |
| 82746 | <1% | 30 | $155.05 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 68 | $150.81 |
| 80354 | <1% | 462 | $147.26 | |
| A4755 | Blood tubing, arterial and venous combined, for hemodialysis, each | <1% | 132 | $121.97 |
| 97035 | <1% | 36 | $79.98 | |
| 82375 | <1% | 28 | $76.62 | |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | <1% | 26 | $74.96 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 58 | $66.55 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 27 | $65.49 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 13 | $51.17 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 82 | $49.10 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 12 | $47.94 |
| 86592 | <1% | 55 | $47.12 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 98 | $43.75 |
| 83050 | <1% | 26 | $40.33 | |
| 86140 | <1% | 14 | $30.49 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 164 | $28.43 |
| 99411 | <1% | 12 | $25.17 | |
| 99484 | <1% | 12 | $17.26 | |
| 84436 | <1% | 52 | $13.14 | |
| A4362 | Skin barrier; solid, 4 x 4 or equivalent; each | <1% | 36 | $6.02 |
| 84479 | <1% | 30 | $6.00 | |
| A4301 | Implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.) | <1% | 59 | $2.00 |
| 91301 | <1% | 15 | $1.00 | |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | <1% | 26 | $0.02 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 19 | $0.00 |
| 84295 | 0% | 12 | $0.00 | |
| OP636 | 0% | 23 | $0.00 | |
| 82435 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAMOS, RAFAEL (VICE PRESIDENT, REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Eoh Acquisition Group, LLC | East Orange, NJ | $1.88M |
| Eoh Acquisition Group, LLC | East Orange, NJ | $588K |
| Eoh Acquisition Group, LLC | East Orange, NJ | $211K |
| Eoh Acquisition Group, LLC | East Orange, NJ | $112K |
| Physician Associates of Northern New Jersey, PC | East Orange, NJ | $119.72 |
| Eoh Acquisition Group, LLC | East Orange, NJ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.